SUPN vs. PCRX, INVA, CORT, ARQT, OCUL, ORIC, PHAT, KPTI, BTAI, and PRGO
Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Pacira BioSciences (PCRX), Innoviva (INVA), Corcept Therapeutics (CORT), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Karyopharm Therapeutics (KPTI), BioXcel Therapeutics (BTAI), and Perrigo (PRGO). These companies are all part of the "medical" sector.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
Pacira BioSciences received 336 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.73% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a net margin of 6.22% compared to Supernus Pharmaceuticals' net margin of 0.22%. Pacira BioSciences' return on equity of 12.81% beat Supernus Pharmaceuticals' return on equity.
99.7% of Pacira BioSciences shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 6.6% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals.
Supernus Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
Supernus Pharmaceuticals currently has a consensus price target of $41.00, indicating a potential upside of 34.78%. Pacira BioSciences has a consensus price target of $49.50, indicating a potential upside of 86.79%. Given Pacira BioSciences' higher possible upside, analysts plainly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.
In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 5 mentions for Pacira BioSciences. Supernus Pharmaceuticals' average media sentiment score of 0.00 beat Pacira BioSciences' score of -0.24 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.
Summary
Pacira BioSciences beats Supernus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Supernus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Supernus Pharmaceuticals Competitors List
Related Companies and Tools
